Navigation Links
Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call
Date:10/17/2007

Avigen to host conference call Wednesday, October 24, at 1:30 p.m. EDT

ALAMEDA, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Avigen, Inc. (Nasdaq: AVGN), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, will hold its quarterly conference call to discuss third quarter results on Wednesday, October 24, 2007, at 1:30 p.m. EDT (10:30 a.m. PDT). Kenneth Chahine, Chief Executive Officer, and Michael Coffee, Chief Business Officer, can be heard by calling 888-396-2369 (U.S.) or 617-847-8710 (non-U.S. locations) using passcode 85761637.

This call is being webcast by Thomson/CCBN and can be accessed at Avigen's website at http://www.avigen.com. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

A rebroadcast of the call will be available shortly after the conclusion of the session. The replay may be accessed over the Internet at http://www.avigen.com or by calling 888-286-8010 (U.S.) or 617-801-6888 (non-U.S. locations) using passcode 67087442.

About Avigen

Avigen, Inc. is a biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious, chronic neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. For press releases and other corporate information, visit our website at http://www.avigen.com.


'/>"/>
SOURCE Avigen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... (PRWEB) , ... March 20, ... ... substances that interfere with the ability of endogenous hormones to regulate homeostasis ... ligand binding activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and immunological ...
(Date:3/20/2017)... ... March 20, 2017 , ... Existing methods using LC-MS/MS suffer ... to reduce the impact on instrumentation. ICP-MS is a robust and specific analytical ... , This presentation will discuss the pros and cons of using LC-ICP-MS for ...
(Date:3/20/2017)... ... March 20, 2017 , ... Park Systems, a leader in Atomic Force Microscopy ... 24, 2017 from 5-7pm at their Santa Clara facility that will include craft beer ... Researcher, Dr. Tae-Gon Kim. , Dr. Tae-Gon Kim, Senior researcher at imec Belgium and ...
(Date:3/20/2017)... , March 20, 2017  Attorney Advertising -- Bronstein, Gewirtz ... purchasers of the BioAmber Inc. ("BioAmber" or the "Company") (NYSE: ... information and assist the investigation by visiting the firm,s site: ... BioAmber and certain of its officers and/or directors have violated ... 1934. ...
Breaking Biology Technology:
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
(Date:3/7/2017)...   HireVue , the leading provider of video ... best talent, faster, today announced the additions of ... Diana Kucer as Chief Marketing Officer (CMO). ... poised to drive continued growth in the company,s new ... record bookings in 2017. "Companies worldwide turn ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
Breaking Biology News(10 mins):